PSORIATIC ARTHRITIS
RINVOQ, the first ever once-daily oral JAK inhibitor for the treatment of active PsA, AS and RA1
*Primary endpoint was the proportion of patients achieving ACR20 response with RINVOQ vs placebo at Week 12.3
NICE Publishes Positive Technology Appraisal Guidance (TAG) for RINVOQ for treating active psoriatic arthritis in adults2
RINVOQ, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to DMARDs or who cannot tolerate them.
It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and:
• they have had 2 conventional DMARDs and at least 1 biological DMARD or
• TNF-alpha inhibitors are contraindicated but would otherwise be considered.
RINVOQ is recommended only if AbbVie provides it according to the commercial arrangement.
ACR20 = Improvement of at least 20% in the American College of Rheumatology core criteria; AS = Ankylosing Spondylitis; DMARDs = Disease-Modifying Antirheumatic Drugs; JAK = Janus Kinase; MTX = Methotrexate; NICE = National Institute for Health and Care Excellence; PASI 75 = Psoriasis Area and Severity Index 75% improvement; PsA = Psoriatic Arthritis; RA = Rheumatoid Arthritis; TAG = Technology Appraisal Guidance; TNF = Tumour Necrosis Factor.
References
- RINVOQ (upadacitinib) SmPC.
- NICE (2022) Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs; Technology Appraisal Guidance; TA768. Available at: https://www.nice.org.uk/guidance/ta768 (accessed February 2022).
- McInnes IB, et al. N Engl J Med 2021;384;1227-39.
- McInnes IB, et al. RMD Open 2021;7:e001838.
- Nash P, et al. Arthritis Rheumatol 2020; 72(suppl. 10):POS1035.
- van der Heijde D, et al. Lancet 2019;394:2108-2117.
- Deodhar A, et al. Arthritis Rheumatol 2020;72(suppl. 10):2023.
- Cohen SB, et al. EULAR E-Congress 2021;POS0220.
UK-UPAD-210367. Date of preparation: February 2022.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com